BioTuesdays

Tag - Swayampakula Ramakanth

MiMedx Group
Markets

HCW starts MiMedx at buy; PT $20

H.C. Wainwright launched coverage of MiMedx Group (NASDAQ:MDXG) with a “buy” rating and $20 price target. The stock closed at $8.81 on March 18. MiMedx is a wound care industry leader commercializing placental...

March 19, 2021
Plus Therapeutics Logo
Markets

HCW starts Plus Therapeutics at buy; PT $7

H.C. Wainwright launched coverage of Plus Therapeutics (NASDAQ:PSTV) with a “buy” rating and $7 price target. The stock closed at $3.75 on Feb. 10. Plus is focused on developing novel therapies against brain cancer. The...

February 11, 2021
Ocugen
Markets

HCW ups Ocugen to buy from neutral; PT $4.50

H.C. Wainwright upgraded Ocugen (NASDAQ:OCGN) to “buy” from “neutral” with a price target of $4.50, citing a definitive agreement with Bharat Biotech to co-develop, supply, and commercialize Bharat’s COVID-19 vaccine...

February 4, 2021
Medicenna Therapeutics
Markets

HCW starts Medicenna Therapeutics at buy; PT $8

H.C. Wainwright initiated coverage of Medicenna Therapeutics (NASDAQ:MDNA) with a “buy” rating and price target of $8. The stock closed at $3.88 on Sept. 8. Medicenna is an immuno-oncology company developing therapies...

September 10, 2020
electroCore Logo
Markets

HCW ups electroCore PT to $2.50 from $1.50

H.C. Wainwright raised its price target for electroCore (NASDAQ:ECOR) to $2.50 from $1.50, citing the FDA’s emergency use authorization of gammaCore, the company’s lead product, to treat COVID-19 patients. The stock...

July 15, 2020
Pulse Biosciences Logo
Markets

HCW ups Pulse Biosciences PT to $16 from $6

H.C. Wainwright raised its price target for Pulse Biosciences (NASDAQ:PLSE) to $16 from $6, citing the company’s agreement with the FDA on requirements for a 510(k) submission for a general dermatological indication of...

May 12, 2020
Precigen Logo
Markets

HCW starts Precigen at buy; PT $5

H.C. Wainwright initiated coverage of Precigen (NASDAQ:PGEN) with a “buy” rating and $5 price target. The stock closed at $3.17 on May 7. Precigen, previously known as Intrexon, is focused on applying synthetic biology...

May 8, 2020
PolarityTE Logo
Markets

HCW cuts PolarityTE to neutral and removes PT

H.C. Wainwright downgraded PolarityTE (NASDAQ:PTE) to “neutral” from “buy” and removed its price target, citing the clinical and regulatory risk from a strategy shift for its wound closure product, SkinTE. The stock...

May 4, 2020
AVEO Pharmaceuticals Logo
Markets

HCW cuts AVEO Pharma PT to $4 from $6

H.C. Wainwright lowered its price target for AVEO Pharmaceuticals (NASDAQ:AVEO) to $4 from $6, but reiterated a “buy” rating, citing discontinuation of the company’s ficlatuzumab program because of COVID-19 and reduced...

April 1, 2020